Intestinal permeability in patients with chemotherapy-induced stomatitis
- PMID: 11355146
- PMCID: PMC12164931
- DOI: 10.1007/s004320000209
Intestinal permeability in patients with chemotherapy-induced stomatitis
Abstract
Purpose: Mucositis represents one of the most common side effects of chemotherapy, and may affect any part of the gastrointestinal tract, resulting in stomatitis, dysphagia, dyspepsia, or diarrhea. The aim of the present study was to evaluate intestinal permeability in patients with stomatitis during treatment with oral granulocyte-monocyte colony-stimulating factor (GM-CSF, Leucomax).
Methods: Ten patients with chemotherapy-induced stomatitis and 21 control cancer patients were included in the study. Intestinal permeability in patients with stomatitis was evaluated before and after the treatment with oral GM-CSF (200 micrograms for 4 consecutive days) by measuring urinary lactulose, D-xylose, and mannitol after oral challenge in collected urine using capillary gas chromatography.
Results: Mean grade of stomatitis (3, range 2-3) improved during treatment by a mean of 1 grade (range 0-2, sign test P < 0.05) with an improvement observed in eight of ten patients. Lactulose excretion, lactulose/mannitol, and lactulose/xylose ratios were markedly elevated in the patients with mucositis compared with 21 control cancer patients (1.60 +/- 1.04%, 0.2446 +/- 0.2937, and 0.3877 +/- 0.6808 vs 0.35 +/- 0.20%, 0.0332 +/- 0.0148, and 0.0255 +/- 0.0086, respectively, Mann Whitney U-test, P < 0.001). After treatment, lactulose excretion, lactulose/mannitol, and lactulose/xylose ratio decreased significantly (1.60 +/- 1.04 vs 0.63 +/- 0.42%; 0.2446 +/- 0.2937 vs 0.1303 +/- 0.1149; and 0.3877 +/- 0.6808 vs 0.1126 +/- 0.1146, respectively, P < 0.05).
Conclusions: Lactulose excretion after oral challenge, lactulose/mannitol, or lactulose/xylose ratio may be useful markers for intestinal involvement in chemotherapy-induced mucositis. Improvement of oral mucositis was associated with a significant decrease of intestinal permeability to lactulose. Testing of intestinal permeability by the present method may be useful to evaluate the effect of therapeutic interventions in patients with chemotherapy-induced mucositis.
Similar articles
-
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.Lancet Gastroenterol Hepatol. 2024 Aug;9(8):734-744. doi: 10.1016/S2468-1253(24)00119-5. Epub 2024 Jun 10. Lancet Gastroenterol Hepatol. 2024. PMID: 38870977 Clinical Trial.
-
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors.Cochrane Database Syst Rev. 2017 Nov 28;11(11):CD011990. doi: 10.1002/14651858.CD011990.pub2. Cochrane Database Syst Rev. 2017. PMID: 29181845 Free PMC article.
-
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2. Cochrane Database Syst Rev. 2018. PMID: 29624208 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. Cochrane Database Syst Rev. 2011. PMID: 21491413
Cited by
-
Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP).Aging (Albany NY). 2025 Mar 20;17(3):757-777. doi: 10.18632/aging.206224. Epub 2025 Mar 20. Aging (Albany NY). 2025. PMID: 40117561 Free PMC article.
-
Cancer treatment-induced mucositis pain: strategies for assessment and management.Ther Clin Risk Manag. 2006 Sep;2(3):251-8. doi: 10.2147/tcrm.2006.2.3.251. Ther Clin Risk Manag. 2006. PMID: 18360600 Free PMC article.
-
Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis.Invest New Drugs. 2014 Dec;32(6):1301-7. doi: 10.1007/s10637-014-0135-0. Epub 2014 Jul 23. Invest New Drugs. 2014. PMID: 25052233
-
Neopterin as a biomarker of immune response in cancer patients.Ann Transl Med. 2017 Jul;5(13):280. doi: 10.21037/atm.2017.06.29. Ann Transl Med. 2017. PMID: 28758106 Free PMC article. Review.
-
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor.Oncol Lett. 2016 Feb;11(2):939-944. doi: 10.3892/ol.2015.4017. Epub 2015 Dec 9. Oncol Lett. 2016. PMID: 26893672 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources